Advertisement

ASO Author Reflections: The Sentinel Lymph Node in Melanoma: Now More Important Than Ever

  • Michael E. Egger
  • Kelly M. McMasters
ASO Author Reflections
  • 60 Downloads

Notes

Disclosure

Kelly M. McMasters reports that he is on the Board of Directors for Provectus Biopharmaceuticals and serves on the Scientific Advisory Board for Elucida Oncology.

References

  1. 1.
    Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67.CrossRefGoogle Scholar
  2. 2.
    Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22.CrossRefGoogle Scholar
  3. 3.
    Egger ME, Xiao D, Hao H, et al. Unique genes in tumor-positive sentinel lymph nodes associated with nonsentinel lymph node metastases in melanoma. Ann Surg Oncol. 2018;25(5):1296–303.CrossRefGoogle Scholar
  4. 4.
    Egger ME, Callender GG, McMasters KM, et al. Diversity of stage III melanoma in the era of sentinel lymph node biopsy. Ann Surg Oncol. 2013;20(3):956–63.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Hiram C. Polk, Jr, MD Department of SurgeryUniversity of LouisvilleLouisvilleUSA

Personalised recommendations